A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and determining their health care-associated transmission, researchers found.

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

is a technically challenging process and has become vital to interpreting human health. Short-read sequencing (SRS, Illumina sequencing), although less expensive and very accurate, still cannot detect ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology ...

Illumina's (ILMN) stock slid 5% post-market after it released its Q4 earnings report and reiterated its 2025 guidance, ...

Illumina, a gene sequencing company ... the logistics that are a time-consuming part of the clinical trials process. AI agents will help with areas like scheduling and record keeping.